Vivo Capital’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Vivo Capital’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-1,232,394	Closed	-$7.39M	–	53
2022 Q3	$7.39M	Hold	1,232,394	–	–	0.82%	31
2022 Q2	$5.1M	Hold	1,232,394	–	–	0.51%	38
2022 Q1	$4.68M	Hold	1,232,394	–	–	0.32%	43
2021 Q4	$5.55M	Hold	1,232,394	–	–	0.33%	46
2021 Q3	$5.74M	Hold	1,232,394	–	–	0.26%	49
2021 Q2	$8.69M	Hold	1,232,394	–	–	0.38%	45
2021 Q1	$7.28M	Buy	+1,232,394	New	+$7.47M	0.26%	50

Other funds holding STSA

BCM

BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Vivo Capital's STSA Position: Q4 2022 in Review

Vivo Capital sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2022, closing a stake of 1,232,394 shares — an estimated $7.39M sold.

Vivo Capital first reported a position in STSA in Q1 2021 and held it in 7 quarters. The position peaked at $8.69M in Q2 2021. 33 funds tracked by Wall St. Rank hold STSA as of Q4 2022.

Vivo Capital reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Vivo Capital sold 1,232,394 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $7.39M.
Vivo Capital first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q1 2021 and held it in 7 quarters.
Vivo Capital's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $8.69M in Q2 2021.
33 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Vivo Capital's 13F filing for Q4 2022, filed 13 Feb 2023.